impact factor



Anti-TNF-α therapy in the management of severe neurosarcoidosis: a report of five cases from a single centre and literature review

, , , , , , , , , ,


2014 Vol.32, N°2
PI 0275, PF 0284

Free to view
(click on article PDF icon to read the article)

PMID: 24321604 [PubMed]

Received: 20/07/2013
Accepted : 08/11/2013
In Press: 09/12/2013
Published: 09/04/2014


Neurologic manifestations are found in 5-15 % of patients with sarcoidosis. This granulomatous disease may affect any part of the peripheral or the central nervous system, being potentially severe and difficult to treat. Corticosteroids are the cornerstone of therapy in sarcoidosis. However, some patients become resistant or experience side effects to corticosteroids. In these patients, second line therapies including immunosuppressive drugs such as methotrexate, azathioprine, mycophenolate, cyclophosphamide and leflunomide have been used. Anti-TNF-α drugs have been proposed as a therapeutic option for those who are refractory to immunosuppressive drugs or initially in cases of severe sarcoidosis. We report on 5 patients with neurosarcoidosis treated with anti-TNF-α drugs in our center. A literature review of patients with neurosarcoidosis treated with anti-TNF-α drugs was conducted. In our series successful response to anti-TNF-α therapy was achieved. However, the high frequency of relapses following anti-TNF-α discontinuation makes necessary a close follow-up of these patients when the biologic agent is stopped.

Rheumatology Article